v3.25.4
Segment Information
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Information

12. Segment Information

The Company operates and manages its business as one reportable and operating segment, which is the business of developing therapies for autoimmune diseases and cancers. The Company’s chief operating decision maker (CODM) is the chief executive officer, who assesses performance of the segment based on net loss, which includes evaluating the progress of ongoing clinical trials. The measure of segment assets is reported on the balance sheet as total assets. All long-lived assets are maintained in the United States. The following table contains information on segment profit or loss, including significant segment expenses (in thousands):

 

 

YEAR ENDED DECEMBER 31,

 

 

2025

 

 

2024

 

Revenue

 

$

—

 

 

$

251

 

Less:

 

 

 

 

 

 

       AB-101 (AlloNK)

 

 

32,379

 

 

 

19,978

 

       Other programs(a)

 

 

23

 

 

 

330

 

       Personnel-related

 

 

39,285

 

 

 

30,465

 

       Other(b)

 

 

18,123

 

 

 

16,760

 

Other income, net

 

 

5,945

 

 

 

1,909

 

Net loss

 

$

(83,865

)

 

$

(65,373

)

 

(a)
Other programs primarily include costs associated with AB-201.
(b)
Other primarily includes consultant, depreciation, rent, common area maintenance, lab supplies, legal, and insurance expenses.